The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with the XVRd (short for Selinexor, Bortezomib, Lenalidomide, Dexamethasone) regimen in combination with the CART-ASCT-CART2 in newly diagnosed multiple myeloma patients with P53 gene abnormalities. Patients received 3 courses of induction therapy with X-VRd followed by a first infusion of CAR-T cells. Patients then received 3 courses of XVR consolidation therapy, followed by ASCT and second infusion of CAR-T cells. XR maintenance therapy starts on day 100 after ASCT
This is a single-arm, open-label study to evaluate the efficacy and safety of XVRD(Selinexor, Bortezomib, Lenalidomide and Dexamethasone) regimen combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed multiple myeloma with p53 gene abnormalities.